不同类型慢性肝病糖脂代谢紊乱研究进展
DOI: 10.3969/j.issn.1001-5256.2022.08.043
利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:王倩负责课题设计,拟定写作思路,资料收集及撰写论文;张宸瑞负责课题设计及资料收集;唐映梅负责指导撰写文章并最后定稿。
Research advances in glucose and lipid metabolism disorders in different types of chronic liver diseases
-
摘要: 肝脏是机体重要的代谢器官,研究表明慢性肝病与糖脂代谢障碍密切相关,不同类型肝病之间往往表现出不同的糖脂代谢特点。本文综述了不同类型慢性肝病糖脂代谢特点的流行病学特点、疾病严重程度、发病机制及治疗方法,旨在提高临床医生的相关认识。Abstract: The liver is an important metabolic organ in the body. Studies have shown that chronic liver disease is closely associated with glucose and lipid metabolism disorders, and different types of liver diseases often show different characteristics of glucose and lipid metabolism. This article reviews the epidemiological characteristics, disease severity, pathogenesis, and treatment methods of glucose and lipid metabolism disorders in different types of chronic liver diseases, so as to improve the awareness among clinicians.
-
[1] CHALASANI N, YOUNOSSI Z, LAVINE JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67(1): 328-357. DOI: 10.1002/hep.29367. [2] YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431. [3] DULAI PS, SINGH S, PATEL J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis[J]. Hepatology, 2017, 65(5): 1557-1565. DOI: 10.1002/hep.29085. [4] BROUHA SS, NGUYEN P, BETTENCOURT R, et al. Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study[J]. Eur Radiol, 2018, 28(4): 1345-1355. DOI: 10.1007/s00330-017-5075-6. [5] MANTOVANI A, ZAZA G, BYRNE CD, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis[J]. Metabolism, 2018, 79: 64-76. DOI: 10.1016/j.metabol.2017.11.003. [6] TILG H, MOSCHEN AR, RODEN M. NAFLD and diabetes mellitus[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(1): 32-42. DOI: 10.1038/nrgastro.2016.147. [7] HAN CY. Update on FXR biology: Promising therapeutic target?[J]. Int J Mol Sci, 2018, 19(7): 2069. DOI: 10.3390/ijms19072069. [8] PROPERZI C, O'SULLIVAN TA, SHERRIFF JL, et al. Ad libitum mediterranean and low-fat diets both significantly reduce hepatic steatosis: a randomized controlled trial[J]. Hepatology, 2018, 68(5): 1741-1754. DOI: 10.1002/hep.30076. [9] VILAR-GOMEZ E, VUPPALANCHI R, DESAI AP, et al. Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis[J]. Aliment Pharmacol Ther, 2019, 50(3): 317-328. DOI: 10.1111/apt.15331. [10] KHAN RS, BRIL F, CUSI K, et al. Modulation of insulin resistance in nonalcoholic fatty liver disease[J]. Hepatology, 2019, 70(2): 711-724. DOI: 10.1002/hep.30429. [11] ARMSTRONG MJ, GAUNT P, AITHAL GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study[J]. Lancet, 2016, 387(10019): 679-690. DOI: 10.1016/S0140-6736(15)00803-X. [12] KHNEIZER G, RIZVI S, GAWRIEH S. Non-alcoholic fatty liver disease and diabetes mellitus[J]. Adv Exp Med Biol, 2021, 1307: 417-440. DOI: 10.1007/5584_2020_532. [13] REHM J, MATHERS C, POPOVA S, et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders[J]. Lancet, 2009, 373(9682): 2223-2233. DOI: 10.1016/S0140-6736(09)60746-7. [14] REHM J, SAMOKHVALOV AV, SHIELD KD. Global burden of alcoholic liver diseases[J]. J Hepatol, 2013, 59(1): 160-168. DOI: 10.1016/j.jhep.2013.03.007. [15] FORD ES, GILES WH, DIETZ WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey[J]. JAMA, 2002, 287(3): 356-359. DOI: 10.1001/jama.287.3.356. [16] SINGH A, AMIN H, GARG R, et al. Increased prevalence of obesity and metabolic syndrome in patients with alcoholic fatty liver disease[J]. Dig Dis Sci, 2020, 65(11): 3341-3349. DOI: 10.1007/s10620-020-06056-1. [17] GARCIA-COMPEAN D, JAQUEZ-QUINTANA JO, GONZALEZ-GONZALEZ JA, et al. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management[J]. World J Gastroenterol, 2009, 15(3): 280-288. DOI: 10.3748/wjg.15.280. [18] HART CL, MORRISON DS, BATTY GD, et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies[J]. BMJ, 2010, 340: c1240. DOI: 10.1136/bmj.c1240. [19] ÅBERG F, HELENIUS-HIETALA J, PUUKKA P, et al. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population[J]. Hepatology, 2018, 67(6): 2141-2149. DOI: 10.1002/hep.29631. [20] SEITZ HK, BATALLER R, CORTEZ-PINTO H, et al. Alcoholic liver disease[J]. Nat Rev Dis Primers, 2018, 4(1): 16. DOI: 10.1038/s41572-018-0014-7. [21] LECLERCQ S, STÄRKEL P, DELZENNE NM, et al. The gut microbiota: A new target in the management of alcohol dependence?[J]. Alcohol, 2019, 74: 105-111. DOI: 10.1016/j.alcohol.2018.03.005. [22] POLYZOS SA, KOUNTOURAS J, MANTZOROS CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics[J]. Metabolism, 2019, 92: 82-97. DOI: 10.1016/j.metabol.2018.11.014. [23] CONASON A, TEIXEIRA J, HSU CH, et al. Substance use following bariatric weight loss surgery[J]. JAMA Surg, 2013, 148(2): 145-150. hppts: //doi. org/10.1001/2013. jamasurg. 265. DOI: 10.1001/2013.jamasurg.265 [24] LI L, WU LT. Substance use after bariatric surgery: A review[J]. J Psychiatr Res, 2016, 76: 16-29. DOI: 10.1016/j.jpsychires.2016.01.009. [25] World Health Organization. World Health Statistics 2021[EB/OL]. https://www.who.int/health-topics/hepatitis#tab=tab_1. [26] LEE WG, WELLS CI, MCCALL JL, et al. Prevalence of diabetes in liver cirrhosis: A systematic review and meta-analysis[J]. Diabetes Metab Res Rev, 2019, 35(6): e3157. DOI: 10.1002/dmrr.3157. [27] SPRADLING PR, SIMONS B, NARAYANAN M, et al. Incidence of diabetes mellitus in a population-based cohort of persons with chronic hepatitis B virus infection[J]. J Viral Hepat, 2013, 20(7): 510-513. DOI: 10.1111/jvh.12071. [28] CAI C, ZENG J, WU H, et al. Association between hepatitis B virus infection and diabetes mellitus: A meta-analysis[J]. Exp Ther Med, 2015, 10(2): 693-698. DOI: 10.3892/etm.2015.2537. [29] DAI CY, YEH ML, HUANG CF, et al. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles[J]. J Gastroenterol Hepatol, 2015, 30(5): 879-884. DOI: 10.1111/jgh.12313. [30] HSIANG JC, GANE EJ, BAI WW, et al. Type 2 diabetes: a risk factor for liver mortality and complications in hepatitis B cirrhosis patients[J]. J Gastroenterol Hepatol, 2015, 30(3): 591-599. DOI: 10.1111/jgh.12790. [31] ELKRIEF L, CHOUINARD P, BENDERSKY N, et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C[J]. Hepatology, 2014, 60(3): 823-831. DOI: 10.1002/hep.27228. [32] RODRÍGUEZ-ESCAJA C, Á NAVASCUÉS C, GONZÁLEZ-DIÉGUEZ L, et al. Diabetes is not associated with an increased risk of hepatocellular carcinoma in patients with alcoholic or hepatitis C virus cirrhosis[J]. Rev Esp Enferm Dig, 2021, 113(7): 505-511. DOI: 10.17235/reed.2020.6953/2020. [33] YOUNOSSI Z, PARK H, HENRY L, et al. Extrahepatic manifestations of hepatitis C: A Meta-analysis of prevalence, quality of life, and economic burden[J]. Gastroenterology, 2016, 150(7): 1599-1608. DOI: 10.1053/j.gastro.2016.02.039. [34] ELKRIEF L, RAUTOU PE, SARIN S, et al. Diabetes mellitus in patients with cirrhosis: clinical implications and management[J]. Liver Int, 2016, 36(7): 936-948. DOI: 10.1111/liv.13115. [35] SCHATTENBERG JM, SCHUCHMANN M. Diabetes and apoptosis: liver[J]. Apoptosis, 2009, 14(12): 1459-1471. DOI: 10.1007/s10495-009-0366-2. [36] WANG CC, CHENG PN, KAO JH. Systematic review: chronic viral hepatitis and metabolic derangement[J]. Aliment Pharmacol Ther, 2020, 51(2): 216-230. DOI: 10.1111/apt.15575. [37] KOIKE K, TSUTSUMI T. The oncogenic role of hepatitis C virus[J]. Recent Results Cancer Res, 2021, 217: 91-105. DOI: 10.1007/978-3-030-57362-1_5. [38] CACOUB P, DESBOIS AC, COMARMOND C, et al. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis[J]. Gut, 2018, 67(11): 2025-2034. DOI: 10.1136/gutjnl-2018-316234. [39] CIANCIO A, BOSIO R, BO S, et al. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents[J]. J Med Virol, 2018, 90(2): 320-327. DOI: 10.1002/jmv.24954. [40] SETO WK, LAU EH, WU JT, et al. Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study[J]. Aliment Pharmacol Ther, 2017, 45(4): 501-509. hppts: //doi. org/10.1111/apt. 13895. DOI: 10.1111/apt.13895 [41] LOAEZA-DEL CASTILLO AM, GAYTÁN-SANTILLÁN A, LÓPEZ-TELLO A, et al. Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis[J]. Ann Hepatol, 2019, 18(6): 879-882. DOI: 10.1016/j.aohep.2019.07.006. [42] HÍNDI M, LEVY C, COUTO CA, et al. Primary biliary cirrhosis is more severe in overweight patients[J]. J Clin Gastroenterol, 2013, 47(3): e28-e32. DOI: 10.1097/MCG.0b013e318261e659. [43] LIU X, XU H, ZHAN M, et al. The potential effects of diabetes mellitus on liver fibrosis in patients with primary biliary cholangitis[J]. Med Sci Monit, 2019, 25: 6174-6180. DOI: 10.12659/MSM.916107. [44] PANZITT K, JUNGWIRTH E, KRONES E, et al. FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis[J]. J Hepatol, 2020, 72(6): 1122-1131. DOI: 10.1016/j.jhep.2020.01.014. [45] KAUR A, PATANKAR JV, de HAAN W, et al. Loss of Cyp8b1 improves glucose homeostasis by increasing GLP-1[J]. Diabetes, 2015, 64(4): 1168-1179. DOI: 10.2337/db14-0716. [46] ZHAO L, XUAN Z, SONG W, et al. A novel role for farnesoid X receptor in the bile acid-mediated intestinal glucose homeostasis[J]. J Cell Mol Med, 2020, 24(21): 12848-12861. DOI: 10.1111/jcmm.15881. [47] DEUTSCHMANN K, REICH M, KLINDT C, et al. Bile acid receptors in the biliary tree: TGR5 in physiology and disease[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B): 1319-1325. DOI: 10.1016/j.bbadis.2017.08.021. [48] REICH M, KLINDT C, DEUTSCHMANN K, et al. Role of the G protein-coupled bile acid receptor TGR5 in liver damage[J]. Dig Dis, 2017, 35(3): 235-240. DOI: 10.1159/000450917. [49] FLOREANI A, CAZZAGON N, FRANCESCHET I, et al. Metabolic syndrome associated with primary biliary cirrhosis[J]. J Clin Gastroenterol, 2015, 49(1): 57-60. DOI: 10.1097/MCG.0000000000000029. [50] KJÆRGAARD K, FRISCH K, SØRENSEN M, et al. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis[J]. J Hepatol, 2021, 74(1): 58-65. DOI: 10.1016/j.jhep.2020.07.028. [51] GAO Y, LI L, LI B, et al. Response rate and impact on lipid profiles of obeticholic acid treatment for patients with primary biliary cholangitis: A Meta-analysis[J]. Can J Gastroenterol Hepatol, 2021, 2021: 8829510. DOI: 10.1155/2021/8829510.
本文二维码
计量
- 文章访问数: 404
- HTML全文浏览量: 83
- PDF下载量: 56
- 被引次数: 0